Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
EDISON, N.J., June 13, 2017 -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at the 2017 Biotechnology Innovation Organization (BIO) International Convention being held June 19 - 22, 2017 in San Diego, California.
James Sapirstein, Chief Executive Officer of ContraVir, will provide an overview of the Company's business during a live presentation and is available to meet with investors and other companies who are registered to attend the conference. Interested parties may contact ContraVir through the BIO One-on-One Partnering™ system.
| Event: | BIO International Conference | |
| Date: | Wednesday, June 21, 2017 | |
| Time: | 10:45 AM (Pacific Time) | |
| Location: | Theater 3 |
About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative therapy for hepatitis B virus (HBV). The Company is developing two novel anti-HBV compounds with complementary mechanisms of action. TXL™ currently in Phase 2a, is designed to deliver high intrahepatic concentrations of TFV, while minimizing off-target effects caused by high levels of circulating TFV. CRV431, the other anti-HBV compound, is a next-generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV. ContraVir is also developing Valnivudine™, an orally available nucleoside analogue prodrug; Valnivudine™ is currently in Phase 3 for the treatment of herpes zoster. In addition to direct antiviral activity, Phase 2 data suggest that Valnivudine™ has the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN). For more information visit www.contravir.com.
For further information, please contact: Sharen Pyatetskaya Director of Investor Relations [email protected]; (732) 902-4028
